Clinical Trial

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Study acronym: ARISE-2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a prospective, multicenter, open-label, randomized controlled clinical trial. The investigators will apply albumin to the reperfusion treatment of patients with acute ischemic stroke in the anterior circulation. This study aims to verify the efficacy and safety of albumin combined with endovascular treatment in patients with anterior circulation acute ischemic stroke.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-04-16
Trial Details
NCT Number NCT07263308
Lead Sponsor Capital Medical University
Conditions Acute Ischemic Stroke
Enrollment 1,192 participants
Start Date 2025-12-18
Primary Completion 2027-06-20 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-15